PARP inhibitors breast cancer Market 2021 Drivers and Restraints

06/gen/2021 08:13:44 Ankush Nikam Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP inhibitors breast cancer are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors breast cancer developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors breast cancer used to treat subset of ovarian cancer. Currently only PARP inhibitors breast cancer approved in the market is Lynparza from AstraZeneca and several PARP inhibitors breast cancer are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors breast cancer mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.

PARP inhibitors breast cancer Market: Drivers and Restraints

PARP inhibitors breast cancer market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP inhibitors breast cancer market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.

Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

PARP inhibitors breast cancer market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP inhibitors breast cancer over the forecast period. In addition, development of PARP inhibitors breast cancer have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP inhibitors breast cancer over the forecast period.

PARP inhibitors breast cancer Market: Segmentation

PARP inhibitors breast cancer market has been segmented on the basis of drug type, indication, distribution channel and Region.

Based on the drug type, the PARP inhibitors breast cancer market is segmented into the following:

  • Lynparza
  • Niraparib
  • Rucaparib
  • Talazoparib
  • Veliparib

Based on the indication, the PARP inhibitors breast cancer market is segmented into the following:

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

Based on the distribution channel, the PARP inhibitors breast cancer market is segmented into the following:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

PARP inhibitors breast cancer Market: Overview

PARP inhibitors breast cancer market is witnessing significant changes due to increasing opportunity owing to  rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis who’s pipeline PARP inhibitors breast cancer shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP inhibitors breast cancer. PARP inhibitors breast cancer market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.

PARP inhibitors breast cancer Market: Region-wise Outlook

Geographically, PARP inhibitors breast cancer market  is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP inhibitors breast cancer market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP inhibitors breast cancer market by the regions over the forecast period. Asia Pacific PARP inhibitors breast cancer market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region.

To Buy This Research Report @ https://www.futuremarketinsights.com/checkout/3197

PARP inhibitors breast cancer Market: Key Players

Some of the players in the global PARP inhibitors breast cancer market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

ABOUT US:

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact US

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl